Cipla has reported results for first quarter ended June 30, 2014.
The company’s net profit has declined by 30.05% at Rs 332.17 crore as compared to Rs 474.90 crore for the quarter ended June 30, 2013. The company’s total income has decreased by 1.73% to Rs 2511.74 crore for the quarter under review from Rs 2556.05 crore for the corresponding quarter of the previous year.
On the consolidated basis, the Group has reported 39.30% fall in its net profit after taxes & Minority interest at Rs 294.58 crore for the quarter as compared to Rs 485.35 crore for the same quarter in the previous year. However, its total income has increased by 6.98% at Rs 2760.39 crore for quarter under review as compared to Rs 2580.10 crore for the quarter ended June 30, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: